Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study

SORAYA is a global single-arm phase III study evaluating Mirvetuximab soravtansine (MIRV) in patients (pts) with folate receptor alpha (FRα) high platinum-resistant ovarian cancer (PROC). MIRV is an antibody-drug conjugate comprising an FRα-binding antibody, cleavable linker, and maytansinoid DM4, a potent tubulin-targeting agent. In this study, MIRV demonstrated activity in a broad population of PROC, regardless of the number of prior lines of therapy or prior PARPi (Matulonis, SGO 2022). Here we described details of the clinical response to MIRV throughout the treatment journey, which are important for clinical decision making.